Q linea : Strong ASTar results presented at AMCLI

English

Swedish

Published: 2024-03-13 13:45:00 CET Q-Linea AB Investor News Strong ASTar results presented at AMCLI Early study results show ASTar prompted antibiotic therapy modifications in up to 45% of septic patients and enabled appropriate care 20 - 34 hours earlier than current standard-of-care. This weekend, results from two clinical studies on rapid AST were presented at the AMCLI (Associazione Microbiologi Clinici Italiani) National Congress, in Rimini, Italy, at a workshop hosted by Q-linea. Prof. Maurizio Sanguinetti from Università Cattolica del Sacro Cuore, Rome, shared interim results from the LIFETIMES study. Data from ICU patients with bloodstream infections revealed that ASTar prompted antibiotic therapy modifications in 45% of cases, occurring 1.5 days (34.1 hours) earlier than current standard-of-care. Similarly, study results presented by Prof. Alexia Verroken from Cliniques Universitaires Saint-Luc, Brussels, demonstrated that ASTar implementation reduced the time to optimal treatment by nearly 20 hours (19 hours and 53 minutes) compared to routine methods. Prof. Verroken's work indicated that optimal integration of ASTar within the workflow could result in change in therapy selection in one out of four patients. The data presented showed that where ASTar determined clinical impact, 33.3% involved de-escalation, 55% involved escalation and 11.1% involved antibiotic switch. Stuart Gander, CEO & President of Q-linea Group said, "sponsoring clinical research into the impact of rapid AST is part of our strategy to provide healthcare decision-makers with data and insights to improve patient care and outcomes. These findings underscore the significant clinical benefits of using ASTar in bloodstream infection management, across diverse settings and health systems, which have different patient populations and dynamics but nonetheless consistently report improved patient therapy decisions when rapid AST results are available for physicians." About ASTar Instruments and ASTar BC G-Kit ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions. ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States. For more information, please contact: Stuart Gander, President & CEO, Q-linea [e-mail] [phone] Christer Samuelsson, CFO /IR, Q-linea AB [e-mail] [phone] About Q-linea Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com. Attachments: Strong ASTar results presented at AMCLI.pdf This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices To subscribe on regulatory news from this company, go to the subscription page